Lourdes Mengual

List of Publications by Year
in descending order

53 papers	2,040 citations	279798 23 h-index	233421 45 g-index
57 all docs	57 docs citations	57 times ranked	3321 citing authors

#	Article	IF	Citations
1	MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. European Urology, 2011, 59, 671-681.	1.9	401
2	Marked Differences in Protamine Content and P1/P2 Ratios in Sperm Cells From Percoll Fractions Between Patients and Controls. Journal of Andrology, 2003, 24, 438-447.	2.0	154
3	Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 1270-1284.	4.1	131
4	Identification of blood serum micro€RNAs associated with idiopathic and <i>LRRK2</i> Parkinson's disease. Journal of Neuroscience Research, 2014, 92, 1071-1077.	2.9	122
5	Mediterranean Dietary Pattern is Associated with Low Risk of Aggressive Prostate Cancer: MCC-Spain Study. Journal of Urology, 2018, 199, 430-437.	0.4	89
6	Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. International Journal of Cancer, 2013, 133, n/a-n/a.	5.1	88
7	Utility of Fluorescence In Situ Hybridization as a Non-invasive Technique in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma. European Urology, 2007, 51, 409-415.	1.9	73
8	Gene Expression Signature in Urine for Diagnosing and Assessing Aggressiveness of Bladder Urothelial Carcinoma. Clinical Cancer Research, 2010, 16, 2624-2633.	7.0	70
9	A five-gene expression signature to predict progression in T1G3 bladder cancer. European Journal of Cancer, 2016, 64, 127-136.	2.8	67
10	DNA Microarray Expression Profiling of Bladder Cancer Allows Identification of Noninvasive Diagnostic Markers. Journal of Urology, 2009, 182, 741-748.	0.4	65
11	SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Molecular Cancer, 2014, 13, 237.	19.2	60
12	Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1340-1345.	2.5	57
13	Clinical Utility of Fluorescent in situ Hybridization for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-Guérin Therapy. European Urology, 2007, 52, 752-759.	1.9	53
14	Multiplex Protein Signature for the Detection of Bladder Cancer in Voided Urine Samples. Journal of Urology, 2013, 190, 2257-2262.	0.4	42
15	Molecular Lymph Node Staging in Bladder Urothelial Carcinoma: Impact on Survival. European Urology, 2008, 54, 1363-1372.	1.9	40
16	Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clinical Epigenetics, 2018, 10, 71.	4.1	39
17	Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. European Journal of Cancer, 2016, 54, 131-138.	2.8	32
18	Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genetics and Cytogenetics, 2007, 173, 131-135.	1.0	31

#	Article	IF	Citations
19	Multiplex preamplification of specific cDNA targets prior to gene expression analysis by TaqMan Arrays. BMC Research Notes, 2008, 1, 21.	1.4	31
20	Validation Study of a Noninvasive Urine Test for Diagnosis and Prognosis Assessment of Bladder Cancer: Evidence for Improved Models. Journal of Urology, 2014, 191, 261-269.	0.4	30
21	Prognostic value of <scp>microRNA</scp> expression pattern in upper tract urothelial carcinoma. BJU International, 2014, 113, 813-821.	2.5	29
22	Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study. Environment International, 2019, 122, 389-399.	10.0	28
23	Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urology, 2013, 13, 42.	1.4	26
24	Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers. BMC Cancer, 2016, 16, 76.	2.6	22
25	Urinary cell microRNA-based prognostic classifier for non-muscle invasive bladder cancer. Oncotarget, 2017, 8, 18238-18247.	1.8	22
26	Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?. BJU International, 2012, 110, 1310-1316.	2.5	21
27	Molecular characterization of upper urinary tract tumours. BJU International, 2010, 106, 868-872.	2.5	20
28	Partially Degraded RNA from Bladder Washing is a Suitable Sample for Studying Gene Expression Profiles in Bladder Cancer. European Urology, 2006, 50, 1347-1356.	1.9	19
29	Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. BMC Cancer, 2014, 14, 86.	2.6	19
30	Utility of Urothelial mRNA Markers in Blood for Staging and Monitoring Bladder Cancer. Urology, 2012, 79, 240.e9-240.e15.	1.0	17
31	Prognostic value of circulating microRNAs in upper tract urinary carcinoma. Oncotarget, 2018, 9, 16691-16700.	1.8	16
32	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. Cells, 2020, 9, 203.	4.1	15
33	Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clinica Chimica Acta, 2014, 435, 53-58.	1.1	13
34	Chromosomal High-Polysomies Predict Tumour Progression in T1 Transitional Cell Carcinoma of the Bladder. European Urology, 2004, 45, 593-599.	1.9	11
35	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-GuÃ©rin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. Journal of Urology, 2020, 203, 283-291.	0.4	10
36	HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Research, 2010, 30, 2439-45.	1.1	9

#	Article	IF	Citations
37	Perinatal and childhood factors and risk of prostate cancer in adulthood: MCC-Spain case-control study. Cancer Epidemiology, 2016, 43, 49-55.	1.9	8
38	Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study. Oncotarget, 2017, 8, 51522-51529.	1.8	8
39	Fluorescence in situ hybridization analysis of matched primary tumour and lymph-node metastasis of D1 (pT2-3pN1M0) prostate cancer. BJU International, 2004, 94, 407-411.	2.5	7
40	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication. Scientific Reports, 2021, 11, 6132.	3.3	7
41	Quantitative RNA Analysis from Urine Using Real Time PCR. Methods in Molecular Biology, 2018, 1655, 227-237.	0.9	6
42	Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. Translational Research, 2019, 208, 73-84.	5.0	5
43	Urine cytology suspicious for urothelial carcinoma: Prospective follow‐up of cases using cytology and urine biomarker‐based ancillary techniques. Cancer Cytopathology, 2020, 128, 460-469.	2.4	5
44	Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non‐muscle-invasive Bladder Cancer. European Urology Oncology, 2022, 5, 70-83.	5.4	5
45	Prognostic classifier for predicting biochemical recurrence in localized prostate cancer patients after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 493.e17-493.e25.	1.6	4
46	Urine Gene Expression Profiles in Bladder Pain Syndrome Patients Treated with Triamcinolone. European Urology Focus, 2020, 6, 390-396.	3.1	3
47	Semen sampling as a simple, noninvasive surrogate for prostate health screening. Systems Biology in Reproductive Medicine, 2021, 67, 354-365.	2.1	3
48	Clinicopathological and Molecular Prognostic Classifier for Intermediate/High-Risk Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 6338.	3.7	2
49	Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution. Prostate, 2022, 82, 1331-1337.	2.3	2
50	Re: Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. European Urology, 2018, 74, 397.	1.9	1
51	Multiple immunofluorescence assay identifies upregulation of Active Î²-catenin in prostate cancer. BMC Research Notes, 2019, 12, 68.	1.4	1
52	Reply to letter commenting on: A five-gene expression signature to predict progression in T1G3 bladder cancer. European Journal of Cancer, 2016, 68, 198.	2.8	0
53	Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study. Journal of Cancer, 2018, 9, 3208-3215.	2.5	0